This inventor holds 28 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents, primarily in Noribogaine Synthesis. Top assignees: Demerx, Inc., Ici Americas, Inc., Stauffer Chemical Company. Active years: 1977-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
13 out of 37 
3 out of 432 
3 out of 1,304 
Years Active: 1977-2017
Areas of Expertise:
Title: Richard D. Gless: A Pioneer in Pharmaceutical Innovations
Introduction
Richard D. Gless is a notable inventor based in Oakland, CA, who has made significant strides in the field of pharmaceutical innovations. With a total of 28 patents to his name, his contributions have notably advanced the understanding and application of noribogaine derivatives, among other pharmaceutical formulations.
Latest Patents
Among his latest patents, two stand out prominently. The first is related to "Substituted Noribogaine," which encompasses various derivatives, compositions, and methods of use thereof. This invention holds promise in the development of effective pharmaceutical therapies. The second noteworthy patent is titled "Noribogaine Salt Ansolvates," which describes stable noribogaine salt ansolvates. These ansolvates are valuable for preparing pharmaceutical compositions aimed at alleviating nociceptive pain in patients. Richard has formulated a specific preparation method by slurrying solvated forms, particularly MeOH solvated noribogaine hydrochloride in ethanol and water.
Career Highlights
Throughout his impressive career, Richard D. Gless has worked with various prestigious companies, including Demerx, Inc. and Stauffer Chemical Company. His work at these organizations has been instrumental in conducting research and development activities that focus on pharmaceutical innovations and drug formulations.
Collaborations
In his inventive journey, Richard has collaborated with prominent figures in the field of pharmaceuticals, such as Deborah C. Mash and Robert M. Moriarty. These partnerships have fostered groundbreaking research and have contributed to the advancement of their shared objectives in pharmaceutical innovation.
Conclusion
Richard D. Gless continues to be a prominent figure in the realm of pharmaceutical inventions, with his patents paving the way for future discoveries. His contributions are not only impressive in number but also impactful, addressing critical needs in pain management and therapeutic development. The innovations stemming from his work hold the potential to significantly enhance patient care and treatment options in the medical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile